Monoclonal antibody
Type Whole antibody
Source Humanized
Target VEGFA
Clinical data
ATC code none
CAS Number 1531589-13-5
ChemSpider none
Chemical and physical data
Formula C1164H1768N310O372S7
Molar mass 26.31 kDa

Brolucizumab (INN) is a humanized monoclonal antibody designed for the treatment of wet age-related macular degeneration.[1][2]

This drug was developed by Alcon Laboratories, Inc.


  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Brolucizumab, American Medical Association.
  2. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
This article is issued from Wikipedia - version of the 7/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.